ERNEXA THERAPEUTICS
Live / Applied — Extension of time to oppose received (as of 12 Feb 2026)
What this means for you
Not registered yet, but its 28 Mar 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99109342
- Mark type
- Stylized text
- Filed
- 28 Mar 2025
- Published for opposition
- 03 Feb 2026
- Attorney of record
- Ben Natter
Goods and services
- Class 001 — Chemicals: Stem cells for research or scientific purposes; stems cells for medical research
- Class 005 — Pharmaceuticals: Stem cells for medical purposes; Drug delivery systems, namely, implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the treatment of rare diseases tumors, cancer, auto-immune, and inflammatory diseases; stem cell delivery agent in the form of micro-beads for use in stem cell delivery for patients; regenerative medicinal products, namely, cell, cellular component, and stem cell processing and application medical devices for medical application being cell growth media for growing cells for use medical use
- Class 010 — Medical apparatus: Drug delivery systems, namely, implantable subcutaneous drug delivery device in the nature of drug delivery ports; drug delivery systems primarily comprised of drug delivery catheters and medical micro-robots for delivering stem cells into a targeted area in humans; stem cell delivery apparatus for medical use, namely, implantable stem cell delivery ports, medical mic-robots for stem cell delivery; medical biohybrid, synthetic and hybrid micro-robots for use in stem cell delivery for patients; apparatus for the regeneration of stem cells for medical purposes; regenerative medicinal products, namely, cell, cellular component, and stem cell processing and application medical devices for medical application being cell regeneration apparatus; regenerative medicinal products, namely, cell, cellular component, and stem cell extraction medical devices for medical application being needles for medical purposes; medical apparatuses for implementing treatment methods using stem cells
- Class 042 — Scientific and technological services: Research and development in the field of stem-cell therapies; Research and development in the field of stem-cell therapies for treatment of tumors, cancer, auto-immune, and inflammatory diseases; research and development in the field of stem-cell therapies, namely, synthetic induced mesenchymal stem-cell therapies (iMSC); Stem cell research services
- Class 044 — Medical, beauty and agricultural services: Stem cell therapy services; Providing information in the field of stem-cell therapies and stem-cell therapies related to tumors, cancer, auto-immune and inflammatory diseases; stem call bank services; medical services relating to the removal, treatment and processing of stem cells
Owner
- ERNEXA THERAPEUTICS INC., CAMBRIDGE, MA, US
- ERNEXA THERAPEUTICS INC., CAMBRIDGE, MA, US
- Eterna Therapeutics Inc., Cambridge, MA, US
Prosecution history
- 12 Feb 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 03 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Feb 2026 — PUBLISHED FOR OPPOSITION
- 28 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Jan 2026 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 02 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Dec 2025 — EXAMINER'S AMENDMENT ENTERED
- 09 Dec 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 09 Dec 2025 — EXAMINERS AMENDMENT E-MAILED
- 09 Dec 2025 — EXAMINERS AMENDMENT -WRITTEN
- 24 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 24 Nov 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 03 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Sept 2025 — NON-FINAL ACTION E-MAILED